Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion criteria~1. Provision of informed consent prior to any study-specific procedures 2. Men and women 18 to 85 years of age, inclusive, with body mass index (BMI)≤35 3. Subjects need to be non-smokers or ex-smokers (have quit e cigarettes or other inhaled tobacco products ≥6 months before Visit 1) with a total smoking history of less than 10 pack-years (not applicable for e cigarettes) 4. Documented clinical diagnosis of asthma for ≥6 months before Visit 1 5. Subjects on stable medium to high dose ICS (equivalent of budesonide \>400 μg/day) or low to medium dose ICS/LABA for at least 4 weeks prior to screening (Visit 1) (Appendix A, GINA, 2018) 6. Subjects must demonstrate reversibility to inhaled bronchodilators at Visit 2 (a ≥12% and ≥200 mL improvement in FEV1 after administration of a 4 puffs of salbutamol/albuterol) 7. Pre-bronchodilator FEV1 at Visit 3 between 40% and 90% predicted at either -45 or -15 minutes pre-dose 8. At Visit 3, subjects need to be symptomatic on low dose ICS as evidenced by combined daily asthma mean symptom score of \>1 over the previous 7 days or SABA use on ≥3 of the last 7 days during the Run-in Period 9. Demonstrate the ability to use the study inhalation device properly 10. Subject able to perform acceptable pulmonary function testing for FEV1 according to American Thoracic Society/European Respiratory Society (ATS/ERS) acceptability criteria 11. Subject is willing and able to follow study procedures and restrictions. Women of child bearing potential (WOCBP) should be stable on their chosen method of highly effective birth control for a minimum of 3 months prior to Visit 1, and willing to use that for the entire duration of the study (from the time they sign the informed consent), and for 1 month after the last dose of IP 12. For optional inclusion in the Gx component of the study, subjects must provide separate informed consent for the genomic sampling and analysis Exclusion criteria~1. Known or suspected hypersensitivity to any of the IPs, including budesonide, or excipients, including lactose~2. Systemic steroid use within the 6 weeks before Visit 1~3. Concomitant chronic respiratory disease (including current sleep apnea)~4. History or clinical suspicion of any clinically relevant or active disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study, or any other safety concerns in the opinion of the Investigator~5. Use of prohibited medications that cannot be stopped during the entire period of the study (starting Visit 1).~6. Subjects with \<80% eDiary compliance during Run in Period at Visit 3~7. ACQ-5 of ≥3 at Visit 1, Visit 2, or Visit 3~8. Daily rescue use of SABA ≥12 puffs for ≥3 consecutive days at any time during Run-in Period, before randomisation~9. Any clinically important abnormalities in rhythm, conduction or morphology of the digital ECG at rest and any abnormalities in the digital ECG (at Visit 1 or Visit 3) that, as considered by the Investigator, may interfere with the interpretation of QT interval corrected (QTc) interval changes~10. Prolonged QT interval corrected using Fridericia's formula (QTcF) ≥450 msec based on ECG at Visit 1 or Visit 3; or family history of long QT syndrome~11. PR (PQ) interval prolongation (\>240 msec), intermittent second or third degree atrial-ventricular (AV) block or AV dissociation at Visit 1 or Visit 3~12. Subjects with implantable cardiac defibrillator and subjects with sustained symptomatic ventricular and/or atrial tachyarrhythmia~13. Subjects with unstable angina pectoris or stable angina pectoris classified higher than Canadian Cardiovascular Society Class II, or a myocardial infarction or stroke within 6 months before Visit 1~14. History of hospitalisation within 12 months before Visit 1 caused by heart failure or a diagnosis of heart failure higher than New York Heart Association Class II~15. Subjects who are positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody or human immunodeficiency virus (HIV) at Visit 1~16. Donation of blood (≥ 450 mL) within 3 months or donation of plasma within 14 days before Visit 1~17. Suspected poor capability to follow instructions of the study, as judged by the Investigator~18. Previous participation or prior screen failure in the current study, or participation in any other research study within 1 month prior to Visit 1~19. Subject under treatment with biologicals such as monoclonal antibodies or chimeric biomolecules including omalizumab, mepolizumab, and reslizumab within 6 months or 5 half-lives before Visit 1, whichever is longer~20. Subject treated with any investigational drug within 30 days (or 5 half-lives, whichever is longer) prior to Visit 1~21. Positive drug screening result that cannot be justified by subject's medical history and its relevant treatment (over-the-counter product or a valid prescription), or history of or current alcohol or drug abuse (including marijuana and marijuana-containing valid prescriptions), as judged by the Investigator~22. Planned in-patient surgery, major dental procedure or hospitalisation during the study~23. Pregnant woman or lactating woman~24. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff, contract research organisation staff and/or staff at the study centre)~25. Suspicion of Gilbert's syndrome~26. Vulnerable persons (eg, persons kept in detention)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- AZD7594 Dose 1 (Type: EXPERIMENTAL): The randomized subjects will receive AZD7594 55 μg/50 μg (nominal/delivered dose), oral inhalation via dry powder inhaler (DPI) once daily.
- AZD7594 Dose 2 (Type: EXPERIMENTAL): The randomized subjects will receive AZD7594 99 µg/90 µg, oral inhalation via DPI once daily.
- AZD7594 Dose 3 (Type: EXPERIMENTAL): The randomized subjects will receive treatment with AZD7594 198 µg/180 µg, oral inhalation via DPI once daily.
- AZD7594 Dose 4 (Type: EXPERIMENTAL): The randomized subjects will receive treatment with AZD7594 396 µg/360 µg, oral inhalation via DPI once daily.
- AZD7594 Dose 5 (Type: EXPERIMENTAL): The randomized subjects will receive treatment with AZD7594 792 µg/720 µg, oral inhalation via DPI once daily.
- Placebo (Type: PLACEBO_COMPARATOR): The randomized subjects will receive AZD7594 matching placebo oral inhalation via DPI once daily.
- Fluticasone Furoate (Type: ACTIVE_COMPARATOR): The randomized subjects will receive treatment with fluticasone furoate (FF) oral inhalation via DPI, 100 µg per nominal dose, once daily (open-label).

Based on this trial design, predict the completion outcome and termination type (if applicable).